30 closest matches · ranked by relevance
Fasciitis, Necrotizing · Severe Necrotizing Skin and Soft Tissue Infections · Fournier's Gangrene
Primary: Clinical Response to High Dose Daptomycin Therapy at End of Treatment (EOT) — 16; 0; 2; 0 Participants
Necrotizing Soft Tissue Infections · Necrotizing Fasciitis · Fournier's Gangrene
Primary: Number of Patients Achieving Necrotizing Infections Clinical Composite Endpoint (NICCE) — 69; 59; 67; 50 Participants — p=0.135
Necrotizing Soft Tissue Infections
Primary: Number of Subjects With One or More Adverse Events (AEs) During the Treatment Period — 14; 16; 9 Participants
Sepsis
Primary: Mortality — 11 Participants
Infant, Newborn · Infant, Low Birth Weight · Infant, Small for Gestational Age
Primary: Death or Neurodevelopmental Impairment (NDI) — 44; 46; 27; 28 Participants — p=0.03
Skin and Subcutaneous Tissue Bacterial Infections · Gram-Positive Bacterial Infections
Primary: Early Clinical Response at the Early Assessment (EA) Visit in the Intent-to-Treat (ITT) Population — 61; 27; 4; 3 Participants
Diabetic Foot Infections
Primary: Clinical Success (in ITT Population) — 95.7 percentage of participants
Diabetes · Wound Infection · Healthy Volunteers
Primary: Ceftolozane Tissue Penetration — 0.75; 0.87 ratio
Acute Pancreatitis · Intestinal Bacteria Flora Disturbance · Intestinal Dysfunction
Primary: Number of Participants With Gastrointestinal Failure Score Equal 0 — 12; 14 Participants
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Foot Ulcer, Diabetic · Infection
Primary: Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection) — 115; 64; 48 Participants
Clostridium Difficile Infection (CDI)
Primary: Clinical Cure: Resolution of Diarrhea — 54; 44 Participants — p=0.195
Staphylococcus Aureus Bacteremia · Staphylococcus Aureus Endocarditis
Primary: Incidence of Adverse Events [Safety and Tolerability] — 48; 30; 64; 40 Participants
Diabetic Foot
Primary: Number of Participants Experiencing Clinical Failure — 26; 30 Participants
Foot Ulcer, Diabetic · Infection
Primary: Percent of Patients With a Clinical Outcome of Clinical Cure (Resolution of All Clinical Signs and Symptoms of Infection) — 69; 41; 36 percentage of subjects
Complicated Urinary Tract Infection · Acute Pyelonephritis
Primary: Percentage of Subjects With Overall Success at Test-of-Cure — 250; 93; 31; 43 Participants
Diabetic Foot Ulcer
Primary: Number of Participants With a Clinical Cure at Visit 3 (Day 7) — 0; 3 Participants
Skin and Subcutaneous Tissue Bacterial Infections
Primary: The Early Clinical Response Rate — 283; 276 participants
Bacterial Infections · Diabetic Foot · Osteomyelitis
Primary: Number of Patients With Clinical Response of Cure Vs. Failure. — 316; 334; 92; 71 patients
Recurrent Clostridium Difficile Infection · Primary Clostridium Difficile Infection
Primary: Global Absence of Diarrhea Due to Clostridiodes Difficile 8 Weeks After the Start of the Treatment — 4; 9 Participants — p=0.228
Clostridium Difficile Infection · Diarrhea
Primary: Number of Participants With Detectable C. Difficile — 5; 4 Participants
Clostridium Enterocolitis · Pseudomembranous Colitis
Primary: Nitazoxanide — 27 participants
Skin and Subcutaneous Tissue Bacterial Infections
Primary: Early Clinical Response Rate — 264; 266 Responders
Infection; Diabetic Foot
Primary: Percentage of Participants With Favorable Clinical Response Assessments at Discontinuation of Intravenous (IV) Study Therapy (DCIV) — 93.6; 97.3 Percentage of participants
Staphylococcal Infection
Primary: Percentage of Participants Achieving Clinical Cure, Defined as Absence of Clinical Failure, in the Evaluable Population. — 89.5; 88.2; 92.9; 92.7 percentage of…
Serious Systemic Infections · Necrotizing Enterocolitis
Primary: Area Under the Curve at Steady State — 178.0 mg*hr/L
Pneumonia
Primary: Number of Participants With All-Cause Mortality in the Intent-to-Treat (ITT) Population — 103; 95 Participants
Infection With Multi-drug Resistant Organisms
Primary: Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events) — 0; 1 Participants
Complicated Intra-abdominal Infections
Primary: Number of Participants With Clinical Response at the Test of Cure (TOC) Visit — 62; 71 participants
Cellulitis · Skin Infections
Primary: Satisfaction of Discharge Criteria — 15; 14 participants